(Q41561701)

3 October 2017

1 reference

title

Recent advances in graft-versus-host disease (GVHD) prevention (English)

1 reference

3 October 2017

1 reference

1

Blazar BR

1 reference

3 October 2017

3

Vallera DA

1 reference

3 October 2017

Korngold R

2

1 reference

3 October 2017

1 June 1997

1 reference

3 October 2017

Immunological Reviews

1 reference

3 October 2017

157

1 reference

3 October 2017

79-109

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

3 October 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Anti-CD2 antibodies induce T cell unresponsiveness in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CD2 regulates responsiveness of activated T cells to interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Functional expression of B7/BB1 on activated T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CTLA-4 ligation blocks CD28-dependent T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Isolation and characterization of human tonsil dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Isolated human follicular dendritic cells display a unique antigenic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Molecular and biological characterization of a murine ligand for CD40

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

In the absence of a CD40 signal, B cells are tolerogenic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Hierarchical control of lymphocyte survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Purification and characterization of the Fas-ligand that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Macrophage deactivation by interleukin 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent mu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Interaction between CD4 and class II MHC molecules mediates cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D;

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Inability of CD8 alpha' polypeptides to associate with p56lck correlates with impaired function in vitro and lack of expression in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Modelling in peptide design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Mutations in CD8 that affect interactions with HLA class I and monoclonal anti-CD8 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Biological properties of interleukin 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the α2 domain of HLA–A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Monoclonal antibodies to human tumor necrosis factor α: In vitro and in vivo application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Efficacy of anti-CD5 F(ab')2 and Fab' immunoconjugates in human peripheral blood lymphocyte-reconstituted severe combined immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Increased ICAM-1 expression in the early stages of murine chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Erratum: Lethal effect of the anti-Fas antibody in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Mutational analysis of the interaction between CD4 and class II MHC: class II antigens contact CD4 on a surface opposite the gp120-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00976.X

Identification of a monoclonal antibody specific for a murine T3 polypeptide

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1073/PNAS.84.5.1374

Identifiers

DOI

10.1111/J.1600-065X.1997.TB00976.X

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4sopybssyfegvhld75rdjzcgou

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_4sopybssyfegvhld75rdjzcgou

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4sopybssyfegvhld75rdjzcgou

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/4sopybssyfegvhld75rdjzcgou